0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Blenorragia y sulfamidas. Blenorragia: Nociones generales de diagnóstico; tratamiento actual. Sulfamidas: Estudio clínico experimental. Sulfamidoterapia en la blenorragia

JAMA. 1943;121(5):379. doi:10.1001/jama.1943.02840050077034.
Text Size: A A A
Published online

ABSTRACT

The subject matter consists chiefly of the diagnosis and modern treatment of gonorrhea, with clinical and experimental data. Of great interest are those sulfonamide compounds not generally used in the United States, such as uliron, neo-uliron, albucid and rodillone. With uliron Scherber and, independently, Löhe and his co-workers are quoted as claiming 75 per cent cures in 75 and 98 cases respectively. But the author obtained in 54 cases only 19 cures. In 11 per cent of these, prostatitis and epididymitis developed during treatment. With albucid the author quotes von Kennell as curing 86.5 per cent of 200 cases and St. Wolfran of Vienna as curing 98 per cent of 81 cases treated. The author himself, however, finds this drug less effective than sulfapyridine, even though better tolerated. Rodillone has been considered of value by Heitz-Boyer. Durel, however, obtained only 20 per cent cures and felt that the compound's greatest

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();